{"id":"yk-209a-tablet","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Diarrhea"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL3967464","moleculeType":"Small molecule","molecularWeight":"428.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"YK-209A tablet works by inhibiting the PI3K/AKT signaling pathway, which is involved in cell proliferation and survival. This inhibition can lead to the reduction of tumor growth and metastasis. Additionally, YK-209A tablet may also have anti-inflammatory effects.","oneSentence":"YK-209A tablet is a small molecule that targets the PI3K/AKT signaling pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:13.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT05767892","phase":"PHASE3","title":"YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Puhe Pharmaceutical Technology Co., LTD","startDate":"2023-05-01","conditions":"Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":350}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35895,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"YK-209A tablet","genericName":"YK-209A tablet","companyName":"Suzhou Puhe Pharmaceutical Technology Co., LTD","companyId":"suzhou-puhe-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"YK-209A tablet is a small molecule that targets the PI3K/AKT signaling pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}